GENTA INC DE/ Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2011-12-30: Form 8-K; Period of report 2011-12-30; Description 8.01 Other Events; Details 8.01.
- 2011-12-23: Form 8-K; Period of report 2011-12-23; Description 8.01 Other Events; Details 8.01.
- 2011-12-19: Form 8-K; Period of report 2011-12-16; Description 8.01 Other Events; Details 8.01.
- 2011-12-16: Form 8-K; Period of report 2011-12-16; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2011-12-30 | 8-K | 2011-12-30 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 1,344,291,567. | genta_8k-123011.htm |
| 2011-12-23 | 8-K | 2011-12-23 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 1,193,545,637. | genta_8k-122311.htm |
| 2011-12-19 | 8-K | 2011-12-16 | 8.01 Other Events | 8.01 As previously disclosed, on September 2, 2011, Genta Incorporated, a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “September 2011 Purchase Agreement”) with certain accredited investors listed on the signature pages thereto, pursuant to which it agreed to issue up to $12.7 million of units (the “2011 Units”), each 2011 Unit consisting of (i) 12.00% senior secured convertible promissory notes due September 9, 2021, convertible into shares of the Company’s Common Stock, par value $0.001 per share (the “Common Stock”), at an initial conversion rate of 671,040 shares of Common Stock for every $1,000 of principal and accrued interest due under the notes (the “G Notes”), (ii) 12.00% senior secured cash collateralized convertible promissory notes due September 9, 2021, convertible into shares of Common Stock, at a rate of 671,040 shares of Common Stock for every $1,000 of principal and accrued interest due under the notes (the “H Notes”, together with the G Notes, the “September 2011 Notes”), (iii) senior secured convertible promissory note warrants to purchase an amount of G Notes equal to the G Notes purchased at the closing, at an exercise price of $1,000 per warrant (the “G Warrants”), which purchase price may be paid through a cashless “net exercise” feature, and (iv) senior secured cash collateralized convertible promissory note warrants to purchase an amount of G Notes equal to the H Notes purchased at closing, at an exercise price of $1,000 per warrant (the “H Warrants,” together with the G Warrants, the “September 2011 Debt Warrants”), which purchase price may also be paid through a cashless “net exercise” feature. | genta_8k-121611.htm |
| 2011-12-16 | 8-K | 2011-12-16 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 1,062,664,725. | genta_8k-121611.htm |
| 2011-12-08 | 8-K | 2011-12-08 | 8.01 Other Events | 8.01 On December 8, 2011, Genta Incorporated (“the Company”) announced presentation of results from the Company’s Phase 2b clinical trial using tesetaxel as initial, single-agent chemotherapy in women with advanced breast cancer. | genta_8k-120811.htm |
| 2011-12-05 | 8-K | 2011-12-02 | 8.01 Other Events | 8.01 As previously disclosed, on September 2, 2011, Genta Incorporated, a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “September 2011 Purchase Agreement”) with certain accredited investors listed on the signature pages thereto, pursuant to which it agreed to issue up to $12.7 million of units (the “2011 Units”), each 2011 Unit consisting of (i) 12.00% senior secured convertible promissory notes due September 9, 2021, convertible into shares of the Company’s Common Stock, par value $0.001 per share (the “Common Stock”), at an initial conversion rate of 671,040 shares of Common Stock for every $1,000 of principal and accrued interest due under the notes (the “G Notes”), (ii) 12.00% senior secured cash collateralized convertible promissory notes due September 9, 2021, convertible into shares of Common Stock, at a rate of 671,040 shares of Common Stock for every $1,000 of principal and accrued interest due under the notes (the “H Notes”, together with the G Notes, the “September 2011 Notes”), (iii) senior secured convertible promissory note warrants to purchase an amount of G Notes equal to the G Notes purchased at the closing, at an exercise price of $1,000 per warrant (the “G Warrants”), which purchase price may be paid through a cashless “net exercise” feature, and (iv) senior secured cash collateralized convertible promissory note warrants to purchase an amount of G Notes equal to the H Notes purchased at closing, at an exercise price of $1,000 per warrant (the “H Warrants,” together with the G Warrants, the “September 2011 Debt Warrants”), which purchase price may also be paid through a cashless “net exercise” feature. | genta_8k-120211.htm |
| 2011-11-10 | 8-K | 2011-11-10 | 2.02 Results of Operations and Financial Condition | 2.02 On November 10, 2011, Genta Incorporated issued a press release announcing financial results and corporate highlights for the quarter and nine-month period ended September 30, 2011. | genta_8k-111011.htm |
| 2011-10-21 | 8-K | 2011-10-21 | 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 5.07 Genta Incorporated, (the Company), held a Special Meeting of Stockholders on October 21, 2011. 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 778,665,559. | genta_8k-102111.htm |
| 2011-10-07 | 8-K | 2011-10-07 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 686,746,087. | genta_8k-100711.htm |
| 2011-09-23 | 8-K | 2011-09-23 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 609,459,043. | genta_8k-092311.htm |
| 2011-09-16 | 8-K | 2011-09-16 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 595,535,162. | genta_8k-091611.htm |
| 2011-09-09 | 8-K | 2011-09-09 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 429,392,767. | genta_8k-090911.htm |
| 2011-09-06 | 8-K | 2011-09-06 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. | genta_8k-090611.htm |
| 2011-08-11 | 8-K | 2011-08-11 | 2.02 Results of Operations and Financial Condition | 2.02 On August 11, 2011, Genta Incorporated issued a press release announcing financial results and corporate highlights for the quarter and six-month period ended June 30, 2011. | genta_8k-081111.htm |
| 2011-07-29 | 8-K | 2011-07-29 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 219,147,258. | genta_8k-072911.htm |
| 2011-07-08 | 8-K | 2011-07-08 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Genta Incorporated, (the Company), held its 2011 Annual Meeting of Stockholders on July 8, 2011. | genta_8k-070811.htm |
| 2011-07-08 | 8-K | 2011-07-08 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 209,189,832. | genta_8k-070811shares.htm |
| 2011-06-29 | 8-K | 2011-06-29 | 8.01 Other Events | 8.01 On June 29, 2011, Genta Incorporated provided a comprehensive update of its clinical trials programs with tesetaxel, the Company’s lead investigational drug. | genta_8k-062911.htm |
| 2011-06-24 | 8-K | 2011-06-24 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 201,345,676. | genta_8k-062411.htm |
| 2011-06-10 | 8-K | 2011-06-10 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 191,745,094. | genta_8k-061011.htm |
| 2011-06-08 | 8-K | 2011-06-08 | 8.01 Other Events | 8.01 On June 8, 2011, Genta Incorporated announced updated results from multiple dose-ranging trials of tesetaxel, the leading oral taxane in clinical development. | genta_8k-060811.htm |
| 2011-06-03 | 8-K | 2011-06-03 | 8.01 Other Events | 8.01 On June 3, 2011, Genta Incorporated announced updated interim results from a trial of tesetaxel used as 2nd-line treatment in patients with advanced gastric cancer. | genta_8k-060311.htm |
| 2011-06-02 | 8-K | 2011-06-02 | 8.01 Other Events | 8.01 On June 2, 2011, Genta Incorporated announced interim results that show a high objective response rate in an ongoing trial using tesetaxel as initial chemotherapy in women with recurrent breast cancer. | genta_8k-060211.htm |
| 2011-05-27 | 8-K | 2011-05-27 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 181,890,300. | genta_8k-052711.htm |
| 2011-05-23 | 8-K | 2011-05-23 | 8.01 Other Events | 8.01 On May 23, 2011, Genta Incorporated announced that that overall survival for patients treated with Genasense® (oblimersen sodium) Injection plus chemotherapy in AGENDA, the Company’s Phase 3 trial of Genasense® in patients with advanced melanoma, was not significantly superior compared with patients treated with chemotherapy alone. | genta_8k-052311.htm |
| 2011-05-20 | 8-K | 2011-05-20 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 171,598,071. | genta_8k-052011.htm |
| 2011-05-17 | 8-K | 2011-05-17 | 8.01 Other Events | 8.01 On May 17, 2011, Genta Incorporated announced that data from clinical trials of the Company's late-stage compounds, Genasense® (oblimersen sodium) Injection and tesetaxel, will be presented at the 2011 annual meeting of the American Society of Clinical Oncology (ASCO). | genta_8k-051711.htm |
| 2011-05-16 | 8-K | 2011-05-16 | 2.02 Results of Operations and Financial Condition | 2.02 On May 16, 2011, Genta Incorporated issued a press release announcing financial results and corporate highlights for the quarter ended March 31, 2011. | genta_8k-051611.htm |
| 2011-05-06 | 8-K | 2011-05-06 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 151,338,423. | genta_8k-050611.htm |
| 2011-05-03 | 8-K | 2011-05-03 | 8.01 Other Events | 8.01 On May 3, 2011, Genta Incorporated announced that it has initiated a new clinical trial of tesetaxel in Korea as part of a comprehensive global initiative to replace standard taxanes as treatment for patients with advanced gastric cancer. | genta_8k-050311.htm |
| 2011-04-29 | 8-K | 2011-04-29 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 127,246,024. | genta_8k-042911.htm |
| 2011-04-26 | 8-K | 2011-04-26 | 8.01 Other Events | 8.01 On April 26, 2011, Genta Incorporated announced that it has initiated a new clinical trial of tesetaxel in Japan as part of a comprehensive new initiative. | genta_8k-042611.htm |
| 2011-04-21 | 8-K | 2011-04-21 | 8.01 Other Events | 8.01 On April 21, 2011, Genta Incorporated updated its formal guidance for release of results from its Phase 3, randomized, controlled trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma, also known as the AGENDA trial. | genta_8k-042111.htm |
| 2011-04-15 | 8-K | 2011-04-15 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 86,043,542. | genta_8k-041511.htm |
| 2011-04-08 | 8-K | 2011-04-08 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 68,548,750. | genta_8k-040811.htm |
| 2011-03-30 | 8-K | 2011-03-30 | 2.02 Results of Operations and Financial Condition | 2.02 On March 30, 2011, Genta Incorporated issued a press release announcing financial results and corporate highlights for the quarter and year ended December 31, 2010. | genta_8k-033011.htm |
| 2011-03-25 | 8-K | 2011-03-25 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 47,234,779. | genta_8k-032511.htm |
| 2011-03-18 | 8-K | 2011-03-18 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 25,040,243. | genta_8k-031811.htm |
| 2011-03-11 | 8-K | 2011-03-11 | 3.03 Material Modification to Rights of Security Holders | 3.03 As previously reported on March 9, 2010, Genta Incorporated (the “Company”) issued various senior unsecured and secured convertible promissory notes to certain accredited investors in a private placement. | genta_8k-031211.htm |
| 2011-03-04 | 8-K | 2011-03-04 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 14,860,039. | genta_8k-030411.htm |
| 2011-02-17 | 8-K | 2011-02-17 | 8.01 Other Events | 8.01 On December 29, 2010, Genta Incorporated (the “Company”) filed a Current Report on Form 8-K announcing the results of its Special Meeting of Stockholders (the “Special Meeting”). | genta_8k-021711.htm |
| 2011-02-11 | 8-K | 2011-02-11 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 639,985,636. | genta_8k-021111.htm |
| 2011-02-10 | 8-K | 2011-02-10 | 8.01 Other Events | 8.01 On February 10, 2011, Genta Incorporated announced that it has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer. | genta_8k-021011.htm |
| 2011-01-28 | 8-K | 2011-01-28 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 575,123,261. | genta_8k-012811.htm |
| 2011-01-21 | 8-K | 2011-01-21 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 539,371,765. | genta_8k-012111.htm |
| 2011-01-20 | 8-K | 2011-01-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 20, 2011, Genta Incorporated (the “Company”) announced that Douglas G. Watson, resigned from the Board of Directors (the “Board”) of the Company and from his positions as Lead Director of the Board, Chairman of the Compensation Committee of the Board and Chairman of the Audit Committee of the Board. | genta_8k-011611.htm |
| 2011-01-14 | 8-K | 2011-01-14 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 414,248,648. | genta_8k-011411.htm |
| 2011-01-11 | 8-K | 2011-01-11 | 8.01 Other Events | 8.01 On January 11, 2011, Genta Incorporated provided an update of its research and development activities through the issuance of a press release, which is attached as exhibit 99.1. | genta_8k-011111.htm |
| 2011-01-07 | 8-K | 2011-01-07 | 8.01 Other Events | 8.01 The number of outstanding shares of Genta Incorporated common stock par value $0.001 as of the date of this filing is 261,170,969. | genta_8k-010711.htm |
| 2011-01-03 | 8-K | 2011-01-01 | 3.03 Material Modification to Rights of Security Holders | 3.03 As previously reported on March 9, 2010, Genta Incorporated (the “Company”) issued various senior unsecured and secured convertible promissory notes to certain accredited investors in a private placement. | genta_8k-010111.htm |
| 2011-01-03 | 8-K | 2010-12-29 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Genta Incorporated, (the Company), held a Special Meeting of Stockholders on December 29, 2010. | genta_8k-122910.htm |